摘要
Abstract
Objective To investigate the clinical efficacy of combined alprostadil and terlipressin in treatment of cirrhosis complicated with refractory liver ascites.Methods A total of 96 patients with cirrhosis complicated with refractory ascites treated in our hospital from February 2014 to March 2016 were selected and divided into study group and control group of 48 patients ac-cording to random number table method.Both groups received basic treatment and alprostadil and the study group was also given terlipressin treatment.Then the difference of curative effect of two groups was compared.Results Before treatment,there were no significant differences in the diameters and the blood flow velocity of portal vein and splenic vein,serum NO,ET and endotoxin lev-els,abdominal circumference,ascites depth and 24h urine output between two groups(P>0.05).After treatment,the diameter of portal vein and splenic vein,serum NO,ET and endotoxin,abdominal circumference and ascites depth of study group were lower than those of control group,the difference of which was statistically significant(P<0.05).The blood flow velocity of portal vein and splenic vein and 24h urine output of study group were significantly higher than those of control group(P<0.05).After treat-ment,the ascites of 25.00%patients of study group faded to gradeⅠ,43.75%to gradeⅡ,27.08%to gradeⅢ,and there was no effect of last 4.17%patients.The ascites of 12.50%patients of the control group faded to gradeⅠ,37.50%to gradeⅡ,35.52%to grade Ⅲand there was no effect of last 14.58%patients.The efficacy of study group was significantly better than that of control group(P<0.05).Conclusion Combined basic treatment,prostaglandin and terlipressin is more effective in treating cirrhosis complicated with refractory ascites,which can significantly improve the internal diameter and blood flow velocity of portal vein and splenic vein,and reduce the amount of ascites in patients.关键词
肝硬化/难治性/腹水/前列地尔/特利加压素Key words
cirrhosis/refractory/ascites/alprostadil/terlipressin分类
医药卫生
